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Abstract
Introduction: Sickle cell anemia and thalassemia result in impaired bone health in both adults and youths. Children with
other types of chronic hemolytic anemia may also display impaired bone health.
Study Design: To assess bone health in pediatric patients with chronic hemolytic anemia, a cross-sectional study was
conducted involving 45 patients with different forms of hemolytic anemia (i.e., 17 homozygous sickle cell disease and 14
hereditary spherocytosis patients). Biochemical, radiographic and anamnestic parameters of bone health were assessed.
Results: Vitamin D deficiency with 25 OH-vitamin D serum levels below 20 ng/ml was a common finding (80.5%) in this
cohort. Bone pain was present in 31% of patients. Analysis of RANKL, osteoprotegerin (OPG) and osteocalcin levels indicated
an alteration in bone modeling with significantly elevated RANKL/OPG ratios (control: 0.08+0.07; patients: 0.26+0.2,
P= 0.0007). Osteocalcin levels were found to be lower in patients compared with healthy controls (68.5+39.0 ng/ml vs.
118.0+36.6 ng/ml, P= 0.0001). Multiple stepwise regression analysis revealed a significant (P,0.025) influence of LDH
(partial r2 = 0.29), diagnosis of hemolytic anemia (partial r2 = 0.05) and age (partial r2= 0.03) on osteocalcin levels. Patients
with homozygous sickle cell anemia were more frequently and more severely affected by impaired bone health than
patients with hereditary spherocytosis.
Conclusion: Bone health is impaired in pediatric patients with hemolytic anemia. In addition to endocrine alterations, an
imbalance in the RANKL/OPG system and low levels of osteocalcin may contribute to this impairment.
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Introduction
Chronic hemolytic anemia is a rare condition characterized by
an abnormal breakdown of erythrocytes. A plethora of pathogenic
factors can promote the development of chronic hemolysis
(reviewed by Dhaliwal et al. [1]). Intrinsic hemolytic anemia can
be subclassified as membranopathy (e.g., spherocytosis), hemoglo-
binopathy (e.g., sickle cell disease) or enzymopathy (e.g., pyruvate
kinase deficiency). In contrast, extrinsic hemolytic anemias are
caused by conditions such as autoimmunity or microangiopathy.
Impaired bone health has been described in patients with sickle
cell disease and thalassemia. These patients display altered
parameters of bone metabolism and bone mineral density [2–5].
Vitamin D and growth hormone deficiency, chronic transfu-
sion, iron toxicity, as well as diabetes and other endocrine
pathologies have been identified to promote osseous pathology [6].
Certain lifestyle parameters, such as smoking or lack of physical
activity, also have a detrimental impact on bone health [6].
Analysis of a murine model of hemolytic anemia (plasmodium
chabaudi infection or phenylhydrazine treatment) has indicated
that anemia itself may be detrimental to bone health. Moreau
et al. [7] have demonstrated that mice with severe acute hemolytic
stress displayed reduced bone mineral density and decreased levels
of the bone formation marker osteocalcin.
Recently, a number of reports have emerged suggesting an
imbalance in bone remodeling in adult patients with sickle cell
disease or thalassemia, as indicated by an elevated RANKL/OPG
ratio or increased TRAP5b activity [8–10].
However, to our knowledge, few data are available regarding
bone health in pediatric patients, especially for patients with rare
forms of hemolytic anemia, such as hereditary spherocytosis or
glucose-6-phosphate deficiency.
To assess pediatric bone health in these conditions, we
conducted a cross-sectional study of bone health in pediatric
patients with hemolytic anemia.
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Results
Bone health in pediatric patients with hemolytic anemia
The descriptive statistics of the 45 patients and controls are
shown in Tables 1 and 2. Male and female patients did not
significantly differ with respect to biochemical or clinical findings
(data not shown).
A vitamin D deficiency (serum 25-OH vitamin D,20 ng/ml)
was present in 79.6% of the patients, 43.2% of patients displayed
severe vitamin D deficiency (serum 25-OH vitamin D,10 ng/ml).
The mean serum 25-OH vitamin D level was 1267.6 (range: 1–
30.2) ng/ml. Serum 1, 25-(OH)2 vitamin D levels were largely
within the normal range, 49.6619.8 (range: 18–118) ng/l. Mean
serum PTH levels were in the upper normal range, 49.1635.9
(range: 17.3–239.6) pg/ml. However, hyperparathyroidism devel-
oped in more than 20% of the children. For the complete results of
parameters relevant to bone metabolism refer to Tables 1 and 2.
In the subgroup of patients in whom bone mineral density were
assessed via dual-energy X-ray absorptiometry (DXA) scan, the
mean Z-score was negative (20.7461 (22.5 to 0.7, n = 14),
although most readings were within the normal range. Osteopenia
(Z-score ,22) was detected in 14% of the patients screened.
The mean calcium:creatinine ratio in spot urine was low,
0.0760.07 (0.01–0.32) mg/mg.
The calcium:creatine ratio in urine positively correlated with
25-OH vitamin D levels in patients with hemolytic anemia
(r = 0.36, P=0.03, Figure 1).
Mean osteocalcin levels were 75651.1 (17.5–247 ng/ml) as
compared to 115.3635.2 (72.6–186.1 ng/ml) in healthy controls.
45% of all patients had an osteocalcin serum level below the 25th
percentile for age, and approximately 16% of patients were below
the 2.5th percentile. IGF-1 SDS values were negative in most of
the population.
Patient values for SAP, BAP, NTX, DPD, leptin and IGF-1
were compared with age appropriate normative values; the results
are displayed in Table 1.
A strong positive correlation between SAP and BAP levels
(r = 0.94, P,0.0001) and between SAP and PTH levels (r = 0.69,
P,0.0001) was observed. A positive correlation was found
between NTX and BAP levels (r = 0.89, P=0.0012, n= 9) and
between NTX and RANK/OPG levels (r = 0.90, P=0.04, n= 5)
in a subgroup of patients in whom both parameters were
measured.
Vitamin D uptake levels, as assessed via questionnaire, were low
in all patients, although they were relatively higher in the HbSS
group (196 U/d vs. 84 U/d). Mean calcium intake/d was
8556438 (range: 305–1984) mg. Average screen time was
2.161.5 (range: 0–5) h/d, and average daily activity was 3.4 h/
d. Furthermore, 12% of the patients had experienced long bone
fractures.
Table 1. Clinical characteristics, parameters of disease activity and bone health.
All patients (n =45) HbSS (n =17) Spherocytosis (n =14) Healthy controls (n =14) P-Value
Female/male 23/22 9/8 7/7 7/8
Age (years) 9.864.4 (1.1–18.4) 9.364.4 (2.2–18.38) 10.4564.4 (2.5–17.9) 10.363.6 (0.8–14.7) 0.45
BMI SDS 0.0161.1 (23.1–2.33) 20.1161.4 (23.10–2.33) 0.2260.76 (21.58–1.44) 20.1661.17 (22.05–1.83) 0.32
Pubic hair stage SDS 20.1560.69 (22.24–1.18) 20.2860.64 (21.73–0.66) 9 0.1460.42 (20.64–0.87) 8 0.1061.0 (21.4–1.6), 10 0.38
TV/Breast stage SDS 20.1760.93 (22.73–1.94) 20.2060.7 (21.37–0.63) 8 0.3361.0 (21.34–1.94) 8 0.2161.2(21.35–1.82), 10 0.43
Height SDS 20.2760.87 (22.65–1.46) 20.1760.9 (21.81–1.45) 0.1660.6 (20.79–1.23) 20.0962.3 (23.79–3.74) 0.39
LDH (U/l) 4146188.6 (164–) 44 569.46138.4 (386–979) 17 283.1642.4 (213–362) 13 214.5636.4 (168–255) 6 ,0.0001
Bili (mg/dl) 2.5361.64 (0.2–6.9) 44 3.0861.1 (1.5–5.5) 3.0361.9 (1.0–6.9) 13 0.5360.3 (0.3–1.1) 7 ,0.001
Retic (0/00) 136.16107.4 (9–352) 39 195693.6 (69–352) 15 1356108 (9.0–340) 14 NA 0.08
25-OH Vit D (ng/ml) 12.667.9 (1–30.2) 44 9.367.4 (1–25.2) 19.165.7 (12.8–30.2) 14 10.868.8 (1–20.6) 4 0.004
1,25-OH Vit D (pg/ml) 48.4619.8 (18–118) 37 46.6613.7 (18–68) 15 51.5630.2 (23–118) 11 NA 0.73
SAP (U/l) 216.26106.7 (47–646) 44 212.7684.4 (67–417) 173.2678.8 (47–311) 13 231.4657.12 (171–332) 7 0.25
BAP (U/l) 131.4685.0 (26.4–531.4) 44 124.6655.1 (41.5–261) 111.9662.7 (26.4–247) 11 NA 0.002
PTH (pg/ml) 47.1634.8 (17.3–239.6) 44 43.7619.3 (23.0–89.7) 37.6615.6 (17.3–72.1) 14 42.266.44 (35.9–50.0) 4 0.45
NTX (nmolBCE/nmol crea) 715.26648.9 (117–1994) 10 952.56732 (163–1994) 6 117 (N = 1) NA NA
DPD (mg/g crea) 157.0677.9 (20–310) 29 187.2681.4 (63–310) 12 124.1670.8 (20–216) 10 NA 0.11
Ca:Crea (mg/mg) 0.0760.07 (0.01–0.31) 37 0.0560.04 (0.004–0.16) 16 0.0860.07 (0.01–0.25) 10 NA 0.24
Osteocalcin (ng/ml) 68.5639.0 (17.5–204) 33 45.6617.6 (17.5–76.6) 12 90.0646.7 (37.5–204.3) 13 115.3635.2 (72.6–186.1) 13 ,0.0001
IGF-1 SDS 20.6261.2 (23.6–1.7) 39 21.0461.37 (23.6–0.9) 14 20.3661.16 (22.0–1.7) 14 1.361.3 (20.2–3.7) 12 ,0.001
RANKL (pmol/l) 0.8760.64 (0.00–2.77) 17 1.1860.72 (0.44–2.77) 8 0.5760.47 (0.0–1.45) 8 0.2960.26 (0.00–0.92) 14 0.002
OPG (pmol/l) 3.2960.55 (2.3–4.4) 17 3.6360.45 (2.9–4.4) 8 2.9360.46 (2.3–3.5) 8 3.4860.64 (2.80–4.70) 14 0.04
DXA (Z-Score) 20.7461.0 (22.5–0.7) 14 20.661.04 (22.2–0.7) 9 20.7 (N = 1) NA NA
Mean6 SD, (range) are displayed. Followed by the number of patients examined if different from total number. (Pubic hair stage SDS (PH SDS), testicular volume/breast
development stage SDS (TV/breast stage SDS), Lactate dehydrogenase (LDH), bilirubin (bili), reticulocytes (retic), 25-OH vitamin D (25-OH Vit D), 1,25-(OH)2 vitamin D
(1,25-OH Vit D), serum alkaline phosphatase (SAP), bone alkaline phosphatase (BAP), parathyroid hormone (PTH), urinary N-terminal telopeptide (NTX), urinary
deoxypyridinoline (DPD), urinary calcium:creatinine ratio (Ca:Crea), osteocalcin, insulin-like growth factor 1 SDS (IGF-1 SDS), receptor activator of nuclear factor kappa-B
(RANKL), osteoprotegerin (OPG) and dual-energy X-ray absorptiometry (DXA) Z-Score) were assessed. P-values refer to Kruskal Vallis test (HBSS vs Spherocytosis vs
Healthy controls) if values are available for all 3 groups, or to Wilcoxon-two-sample test if values are available for HBSS and Spherocytosis only (in cursive).
doi:10.1371/journal.pone.0108400.t001
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25-OH vitamin D levels were significantly lower in patients with
frequent back pain or knee pain associated with exercise, than in
patients without bone pain (15.661.6 vs. 9.961.6 ng/ml,
P=0.027, Figure 2). Serum levels of alkaline phosphatase were
higher in patients with self-reported knee pain (279.8+76.1 U/l)
than in patients without a history of pain (179.5+64.9 U/l,
P=0.0016).
Comparison of bone health in patients with homozygous
sickle cell disease and spherocytosis
The two largest subgroups in this cohort were patients with
homozygous sickle cell anemia (HbSS, n= 17) or spherocytosis
(n = 14). These groups did not differ in terms of age, sex or
pubertal status (Table 1).
Serum levels of 25-OH vitamin D in patients with HbSS were
approximately half of those in patients with spherocytos is. Severe
vitamin D deficiency (,10 ng/ml) was not detected in children
with spherocytosis, but in 80% of the patients with HbSS.
Hyperparathyroidism was observed in 22% of patients with
HbSS, while it was found in 14% of patients with spherocytosis.
Osteocalcin levels differed significantly between patients with
sickle cell disease, spherocytosis and healthy controls (P,0.0001,
Kruskal-Wallis test). Patients with sickle cell disease displayed the
lowest levels of osteocalcin (45.6617.6 ng/ml), which were
significantly lower than those observed in healthy controls
(115.3635.2 ng/ml), (P,0.001, Mann-Whitney-U test with
Bonferroni-Holm correction for multiple testing) and in patients
with spherocytosis (90.0646.7 ng/ml), (P=0.015, Mann-Whitney
test with Bonferroni-Holm correction for multiple testing)
Figure 3.
Serum levels of RANKL were significantly higher in patients
with sickle cell disease than in controls (1.1860.72 pmol/l vs.
0.2960.26 pmol/l, P=0.0002), whereas levels of osteoprotegerin
(OPG) were not altered in these patients. Serum OPG levels were
significantly reduced in spherocytosis patients (2.960.47 pmol/l)
compared with sickle cell disease patients (3.660.4 pmol/l,
P=0.006). There was a trend showing lower levels of OPG in
patients with spherocytosis compared to controls (3.560.6 pmol/l,
NS, Table 1).
The RANKL/OPG ratio was significantly different between
patients with sickle cell disease, spherocytosis and healthy controls
(P=0.0021, Kruskal-Wallis test). Patients with sickle cell disease
displayed the highest ratios for RANKL/OPG (0.3460.24), which
were significantly higher than those observed in healthy controls
Table 2. Altered parameters of bone metabolism [altered bone specific alkaline phosphatase (BAP) or alkaline phosphatase (SAP),
elevated parathyroid hormone (PTH), altered urinary N-terminal telopeptide (NTX) or urinary deoxypyridinoline (DPD)] and
presence of bone pain in patients.
All Patients HbSS Spherocytosis
25-OH Vitamin D,20 ng/ml 80.5% (33/41) 86.7% (13/15) 61.5% (8/13)
25-OH Vitamin D,10 ng/ml 50% (20/41) 80% (12/15) 0% (0/13)
BAP/SAP altered 11.6% (4/43) 13% (2/15) 0% (0/13)
PTH elevated 22.5% (9/40) 21.4% (3/14) 15.3% (2/13)
NTX/DPD altered 8.6% (3/35) 16.7% (2/12) 0% (0/12)
Regular back pain 32.4% (12/37) 41.7% (5/12) 15.3% (2/13)
Knee pain with exercise 19.4% (7/36) 18.2% (2/11) 7.7.% (1/13)
Percentage and fraction (in brackets) of affected patients are displayed.
doi:10.1371/journal.pone.0108400.t002
Figure 1. Serum levels of 25-OH vitamin D levels positively
correlate with calcium to creatinine ratio in urine (P=0.03,
r =0.36) in patients with hemolytic anemia. The predicted values
based on bivariate regression are indicated as solid line.
doi:10.1371/journal.pone.0108400.g001
Figure 2. Serum 25-OH vitamin D levels are significantly lower
in patients who report bone pain (back pain and/or knee pain
with exercise) than in patients without reported bone pain
(left). Statistically significant differences between the groups, deter-
mined via Mann-Whitney test, are indicated with asterisks (*: P,0.05).
doi:10.1371/journal.pone.0108400.g002
Impaired Bone Health in Children with Hemolytic Anemia
PLOS ONE | www.plosone.org 3 October 2014 | Volume 9 | Issue 10 | e108400
(0.0860.07), (P=0.006, Mann-Whitney-U test with Bonferroni-
Holm correction for multiple testing). RANKL/OPG ratios in
patients with spherocytosis were not significantly different from
controls or sickle cell patients. Figure 3.
In a multiple stepwise regression analysis, in which the influence
of the variables age, sex, diagnosis (healthy control, HbSS or
spherocytosis) and LDH was tested on the variables osteocalcin or
RANKL/OPG ratio, a significant effect was detected:
Osteocalcin levels were influenced by LDH (partial r2 = 0.29,
P=0.03), diagnostic group (partial r2 = 0.05, P=0.31) and age
(partial r2 = 0.03, P=0.41). No influence of gender on osteocalcin
levels was found.
RANKL/OPG levels were influenced by age (partial r2 = 0.3,
P=0.24), LDH (partial r2 = 0.11, P=0.13), sex (partial r2 = 0.04,
P=0.37) and diagnosis (partial r2 = 0.03, P=0.46).
Discussion
Bone health in pediatric patients with hemolytic anemia
In our tertiary center, pediatric patients with hemolytic anemia
displayed a high prevalence of vitamin D deficiency. In this group,
patients with sickle cell disease were most frequently affected by
vitamin D deficiency and displayed the lowest 25-OH vitamin D
levels.
As vitamin D is a major regulator of calcium homeostasis, severe
vitamin D deficiency can be accompanied by low calcium stores
and secondary hyperparathyroidism.
We assessed urinary calcium excretion levels in spot urine
samples to estimate overall body calcium balance and found a
significant positive correlation between the calcium:creatinine
ratios and 25 OH-Vitamin D levels. Patients with low 25 OH-
Vitamin D levels also displayed lower calcium:creatinine ratios,
thereby indicating a poor total calcium balance.
Approximately half of the patients with severe vitamin D
deficiency developed secondary hyperparathyroidism. These data
suggest that vitamin D deficiency is not only a common finding, as
previously reported in adult [11] and pediatric [12] patients with
sickle cell disease, but it should be treated to avoid secondary
damage to the skeletal system.
Amongst other hormones, IGF-1 exhibits positive effects on
bone formation (reviewed by Guntur and Rosen [13]). IGF-1
levels in this cohort of patients were subnormal. Low IGF-1 levels
contributing to impaired bone health have previously been
reported for HbSS [14] and thalassemia [15]. However, this
represents the first report of low IGF-1 levels among spherocytosis
patients.
It is relatively difficult to assess bone health, especially in a
pediatric population. Bone mineral denisity (BMD) assessed via
bone densitometry must be corrected for age and height
appropriate standards. Reduced BMD below the 2nd standard
deviation is probably a late and alarming sign of impaired bone
health. As BMD assessment necessitates exposure to x-ray
radiation, it was evaluated exclusively in children with suspected
bone health impairment in this cohort. The average Z-Score was
low with - 0.74. This value is probably biased towards lower values
due to the above mentioned criteria for examination, however, it
has been shown that reduced BMD is a common finding in
pediatric [12] and adult [16] sickle cell disease patients.
Frequent back pain and knee pain after exercise can be
indicative of impaired bone health. We aimed to determine
whether self-reported bone pain and biochemical parameters of
bone metabolism were linked in this cohort of patients.
Figure 3. Parameters of bone remodeling are altered in patients with sickle cell disease. Distribution (lines indicate mean and
standardvariation) of A) osteocalcin and B) RANKL/OPG ratio in patients with sickle cell disease (HbSS. grey circles) and in patients with spherocytosis
(Spherocytosis, black squares) compared to age- and sex-matched healthy controls (Healthy controls, lightgrey triangles) Statistically significant
differences between the groups (as assessed by Mann Whithey-U test with Bonferroni-Holm correction for multiple testing) are indicated with
asterisks (*: P,0.05, **: P,0.01, ***: P,0.001).
doi:10.1371/journal.pone.0108400.g003
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Surprisingly, patients who reported bone pain displayed
significantly lower levels of 25 OH-vitamin D. We also found
that recurring knee pain was associated with higher serum alkaline
phosphatase levels in patients with hemolytic anemia.
An association between vitamin D deficiency and clinical
features of poor musculoskeletal health and especially self-reported
chronic pain has previously been reported [17]. In a follow up
study, the same group has suggested that supplementation of
vitamin D alleviates chronic pain in sickle cell disease patients
[18].
Comparison of bone health in patients with homozygous
sickle cell disease and spherocytosis
Comparing the largest subgroups of this cohort, patients with
sickle cell anemia are significantly more likely to exhibit severe
vitamin D deficiency (,10 ng/ml) than patients with spherocyto-
sis, despite slightly higher intake levels of vitamin D3. It is feasible
that different food preferences or different nutritional recommen-
dations by the primary care physicians result in the difference in
vitamin D3 intake levels. However, even in patients with sickle cell
disease vitamin D3 intake levels were onlyJ of the recommended
daily intake of 800 IU in Germany.
Both bone formation and bone resorption are essential for
physiological bone modeling and remodeling.
In our study, patients with hemolytic anemia displayed
significantly lower levels of osteocalcin (a marker of bone
formation) than the healthy control group. This has been
previously described in pediatric patients with b-thalassemia and
sickle cell disease [3,19] and may reflect an intrinsic deficit in bone
formation in patients with hemolytic anemia.
Patients with hemolytic anemia also displayed a significantly
higher RANKL/OPG ratio compared with the control group.
Binding of RANKL to its receptor results in osteoclast differen-
tiation and stimulation, while OPG serves as a circulating
inactivator of RANKL.
To further analyze these differences we have performed a
nonparametric one way ANOVA which detected significant
differences in osteocalcin and RANK/OPG levels between
patients with sickle cell disease, patients with spherocytosis and
healthy controls. Post-hoc analysis revealed significantly lower
levels of osteocalcin in patients with sickle cell disease, than in any
of the other groups. Conversely, RANK/OPG ratios were
significantly higher in patients with sickle cell disease than in
healthy controls.
Since sickle cell disease, more so than spherocytosis, is a state of
chronic inflammation [20], this fact may contribute to the
activation of the RANK pathway and result in activation of
osteoclasts. In adults with sickle cell disease, Nouraie and
colleagues [8] have reported increased levels of TRAP5b, a
marker of osteoclast activity.
It is also feasible that severe hemolysis may be responsible for
the more pronounced impairment of bone health in patients with
sickle cell disease. We found a significant influence of LDH serum
levels on Osteocalcin and RANK/OPG levels in a multiple
stepwise regression model, indicating that disease activity is
relevant for bone metabolism.
Limitations of the study
The main limitation of the current study is the small size and
heterogeneous nature of the cohort. Due to the small number of
patients, for some of the diagnoses, it was not possible to perform a




The study was performed in the Hematology-Oncology
outpatient clinic of the Children’s Hospital, University of
Duisburg-Essen, Germany, between August 2012 and August
2013. A total of 45 patients (24 females, 21 males) with hemolytic
anemia were recruited during regular visits after informed consent
was obtained from the patients and parents.
The study (German clinical trials register number 00003636)
was performed in accordance with the ethical principles of the
Declaration of Helsinki and was approved by the ‘Research Ethics
Committee of the Medical Faculty, University of Duisburg-Essen’
(12-4966-BO). Patients were included after written informed
consent was obtained from patients and caregivers.
In a subgroup of patients, serum levels of osteocalcin (OC),
receptor activator of nuclear factor kappa-B ligand (RANKL) and
osteoprotegerin (OPG) were assessed and compared with healthy,
age-matched controls. The group of healthy controls consisted of
children who were examined by the endocrine service for
suspected endocrine dysfunction. Parents and children of the
healthy control group gave written informed consent to participate
in the study.
Patients with the following diagnoses were included in the study:
homozygous sickle cell anemia (HbSS, n= 17), sickle hemoglobin
C disease (HbSC, n= 2), b-thalassemia major (n = 6), b-thalasse-
mia minor (n = 1), hereditary spherocytosis (n = 14), glucose-6-
phosphate deficiency (n = 2), paroxysmal nocturnal hemoglobin-
uria (PNH, n= 1) and hemolytic anemia of unknown origin (n = 2).
Four of the patients with b-thalassemia major had undergone
allogeneic bone marrow transplantation. For patient characteris-
tics refer to Table 1.
Laboratory tests
The following biochemical parameters of disease activity,
growth, pubertal status, bone turnover and vitamin D metabolism
were assessed in serum or plasma samples: lactate dehydrogenase,
LDH (U/l); total bilirubin (mg/dl); reticulocytes (0/00); 25-OH
vitamin D (ng/ml); 1,25-(OH)2 vitamin D (pg/ml); serum alkaline
phosphatase, SAP (U/l); bone specific alkaline phosphatase, BAP
(U/l);); parathyroid hormone, PTH (pg/ml); osteocalcin, OC (ng/
ml); insulin-like growth factor-1, IGF-1 (ng/ml); RANKL (pmol/l)
and osteoprotegerin, OPG (pmol/l).
Additionally, N-terminal telopeptide, NTX (nmol bone collagen
equivalent (BCE)/mmol creatinine) and deoxypyridinoline, DPD
(mg/g creatinine), as markers of bone resorption, as well as the
calcium:creatinine ratio (mg/mg) were assessed in spot urine
samples. Serum IGF-1 levels were expressed in SDS values,
according to age and sex, based on the data of Blum and Breier
[21]. For calculations of IGF-1 SDS the software tool ‘‘SDS-
Easy’’, (Mediagnost, Reutlingen, Germany) was used, while serum
leptin levels were expressed in SDS values according to sex, BMI
and Tanner stage [22].
Bone densitometry
Bone mineral density (BMD) was examined via dual-energy X-
ray absorptiometry (DXA) (Lunar Prodigy, GE-Healthcare,
Madison, WI, USA) in a small subgroup of patients. BMD was
assessed at the lumbar spine (L1–L4; anteroposterior view) and the
left femoral neck. Z -scores were calculated for the lumbar spine
measurements based on normative values for the corresponding
age [23]. A single investigator blinded to the clinical status of the
patients was responsible for all BMD measurements.
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Clinical parameters and questionnaire
During regular visits in the outpatient clinic, a physical exam
was performed assessing patient height, weight and pubertal
staging according to Tanner stage.
Standing height was measured using a wall-mounted stadi-
ometer (Ulmer Stadiometer, Busse Design, Elchingen, Germany)
to the nearest mm. Weight was recorded to the nearest 0.1 kg
using a digital scale (Seca, Hamburg, Germany). BMI was
calculated from these data using the formula weight (kg)/(height2)
(m2). The measurements were transformed into SDS (standard
deviation score) based on a reference data set for German children
[24]. An experienced pediatrician assessed the pubertal develop-
ment according to the Tanner stages. Testicular volume was
assessed using a Prader orchidometer. Pubertal status data were
then transformed into SDS based on the data of Mul et al.
Conversion of pubertal stages into SDS was performed using the
web application (http://vps.stefvanbuuren.nl/puberty/) (accessed
2014 July 3) by van Buuren and Ooms [25].
Patients were asked to complete a standardized questionnaire
regarding vitamin D and calcium intake, nutritional supplements,
screen hours per day and hours of physical activity per day.
Specifically, patients and parents were asked to provide data on
the average amounts of: milk, sparkling water (and type of
sparkling water), cereal (and type of cereal), cheese slices, yoghurts,
seeds and fish (including type of fish) per week.
Vitamin D intake was calculated according to data charts,
published by Heseker [26] and Elmadfa et al. [27].
Additionally, patients were interrogated regarding fracture
history and the presence of frequent back pain or knee pain
associated with exercise. The number of transfusions undergone
during the two years prior to the study visit was obtained via chart
review.
Statistics
Data were tested for normal distribution using the Shapiro-Wilk
test. The assumption of a normal distribution was rejected at an
alpha ,0.1. Since a normal distribution could not be assumed for
most parameters, differences between diagnostic groups (healthy
controls, HbSS or spherocytosis) were tested by the Kruskal-Wallis
test. When an overall difference was found, post hoc analysis was
carried out by pairwise comparison of groups using the Mann -
Whitney-U test, correcting for multiple testing with the Bonfer-
roni-Holm method. The influence of age, sex, diagnosis (healthy
controls, HbSS or spherocytosis) and LDH on bone markers was
assessed by multiple stepwise regression analysis. Variables
accepted in the model were significant at the 0.5000 level.
Associations between single variables were described by the
Spearman correlation coefficient. Differences between group
means and reference cohorts were assessed by the Mann-
Whitney-U test. Statistical significance was assumed at P,0.05.
Data are given as mean 61 SD and range. Data analysis was
performed using SAS statistical software (SAS System, release 9.4,
SAS Institute Inc., Carey, NC, USA, 2008).
Conclusions
With this study, we demonstrate that children with hemolytic
anemia share features of impaired bone health. These observations
provide new insight regarding such patients and support the
findings of comparable reports on bone health in adult and
pediatric patients with sickle cell disease and thalassemia [6].
Patients with sickle cell disease display more severe alterations of
bone health than patients with spherocytosis. Therefore, the
pathogenesis and severity of hemolysis may be a critical factor in
determining the phenotype of bone pathology.
This report highlights the need for further studies of bone health
in patients with hemolytic disease. Our findings also suggest that
the paradigm should be modified in that all such patients should
be tested regarding bone health.
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